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A B S T R A C T
Background: Atrial fibrillation (AF) increases the risk of thromboembolic events caused by emboli 
originating in the left atrial appendage (LAA). Mechanical methods for LAA occlusion have been developed 
as an alternative to oral anticoagulation. The aim of this study was to present an initial experience with the 
AMPLATZER® Cardiac Plug. 
Methods:  Patients with permanent or paroxysmal AF and with contraindications or complications of oral 
anticoagulation were included. Patients with LAA anatomy and measures compatible with the occluder, and 
without thrombi, were selected through transesophageal echocardiography. 
Results: A total of 14 procedures were performed in 13 patients (5M:8F), with mean age of 66.7 years. Significant 
bleeding and previous strokes were found in 69.2% and 53.8%, respectively. AF was permanent in 84.6% and 
paroxysmal in the remainder. The mean diameters of the ostium and the landing zone were 23.9 mm and 20.8 
mm, respectively. Bilobulated LAA was observed in 76.9%. Procedures were possible in all cases. Sixteen devices 
were used in 13 patients, a ratio of 1.2:1, and only one patient required a second device for LAA occlusion. The 
mean follow-up was 12.2 months. All LAA remain closed, with no residual defect to date. There was only one 
late death, unrelated to the procedure. 
Conclusions: LAA occlusion using the AMPLATZER® Cardiac Plug device was shown to be safe and effective in 
this small series of patients. The initial results are encouraging and indicate the transcatheter closure of the LAA 
as an alternative to oral anticoagulation therapy in selected patients.
© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Published by Elsevier Editora Ltda. 
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 
 
Oclusão percutânea do apêndice atrial esquerdo com AMPLATZER® Cardiac Plug 
para prevenção de fenômenos tromboembólicos na fibrilação atrial crônica
R E S U M O
Introdução: A fibrilação atrial (FA) aumenta o risco de eventos tromboembólicos por êmbolos originados 
em apêndice atrial esquerdo (AAE). Métodos mecânicos para a oclusão do AAE foram desenvolvidos como 
alternativa à anticoagulação oral. O objetivo deste trabalho foi apresentar uma experiência inicial com o 
AMPLATZER® Cardiac Plug. 
Métodos: Incluímos pacientes com FA permanente ou paroxística, que apresentavam contraindicações ou 
complicações derivadas da anticoagulação oral. Pacientes com anatomia e medidas do AAE compatíveis com o 
oclusor, e sem trombos foram selecionados por meio de ecocardiograma transesofágico. 
Resultados: Foram realizados 14 procedimentos em 13 pacientes (5M:8F), com média de idade de 66,7 anos. 
Sangramento significativo e acidentes vasculares cerebrais prévios foram encontrados em 69,2% e em 53,8%, 
respectivamente. A FA era permanente em 84,6% e paroxística no restante da amostra. Os diâmetros médio 
do óstio e da zona alvo mediram 23,9 mm e 20,8 mm, respectivamente. AAE bilobulados foram observados 
em 76,9%. Os procedimentos foram possíveis em todos os casos. Dezesseis dispositivos foram usados em 13 
pacientes, numa razão de 1,2:1, e apenas 1 paciente precisou de um segundo dispositivo para oclusão do AAE. 
O tempo médio de acompanhamento foi de 12,2 meses. Todos os AAE permanecem fechados e sem defeito 
residual até o momento. Houve apenas um óbito tardio não relacionado ao procedimento. 
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Introduction
Atrial fibrillation (AF) of non-valvular origin is one of the most 
common type of arrhythmia, affecting 1 to 2% of the overall adult 
population.1 It is present in up to 14% of patients older than 65 
years and its incidence doubles every decade.2 Being associated 
with a high risk of cardioembolic events, particularly stroke, AF 
accounts for approximately 15% of all ischemic strokes.3 The risk 
of stroke in patients with AF increases up to five times when com-
pared to patients in sinus rhythm.4
The prevention of embolic phenomena of AF is traditionally 
achieved through the continued use of oral anticoagulants (OAC). 
The most often used OAC are vitamin K antagonists, which are effec-
tive, reducing the incidence of stroke in up to 60% and death in up to 
25% of patients that remain within the therapeutic range.5 The con-
tinued use of these drugs brings several difficulties and inconve-
niences to patients, resulting in a large number of untreated 
individuals. The main problems reported are the risk of bleeding or 
previous episodes of significant bleeding in individuals with predis-
posing conditions; extreme frailty; the low rate of adherence to tre-
atment; harmful drug interactions; the oscillation of therapeutic 
levels of the drug; and unwanted side effects.6-9
The knowledge that more than 90% of emboli in AF originate 
from thrombi in the left atrial appendage (LAA) led to the develop-
ment of options for mechanical obliteration of this structure as an 
alternative therapy to OAC to prevent cerebral thromboembolic 
phenomena.10-12
In this article, the authors report their initial experience with 
LAA occlusion in a single center, using the first dedicated prosthesis 
developed for this purpose and approved for clinical use in Brazil.
Methods
Records of all patients referred for percutaneous closure of the 
LAA in the Interventional Cardiology Department of Structural and 
Congenital Defects of Hospital Federal dos Servidores do Estado in 
the city of Rio de Janeiro (RJ) were retrospectively analyzed.
Patients with permanent or paroxysmal AF and who had contrain-
dications or complications caused by the continued use of OAC were 
selected. Selection for the procedure was attained by transesophageal 
echocardiography (TEE), which included patients whose atrial appen-
dages had anatomical characteristics and diameters compatible with 
the standard occluder used in this service (12.6 mm to 28.5 mm)13 and 
who did not have thrombi inside the LAA.  
The prosthesis used was the AMPLATZER® Cardiac Plug (ACP, 
AGA Medical Corp., Minneapolis, USA), which is a self-expanding 
device made of nitinol, lined with polyester fabric. It consists of a 
cylindrical lobe available in diameters of 16 to 30 mm, with 2-mm 
increments, which corresponds to the nominal size of the prosthe-
sis. Attached to it by a flexible connector pin is a disc; the disc is 
4 mm larger than the lobe in 16 to 22-mm prostheses, and 6 mm 
larger in 24 to 30-mm prostheses.
To increase the safety of the procedure and reduce the risk of de-
vice displacement, six pairs of thin stabilizing hooks are fastened to 
Conclusões: A oclusão do AAE com o dispositivo de AMPLATZER® Cardiac Plug mostrou ser segura e eficaz nesta 
pequena série de pacientes. Os resultados iniciais são encorajadores e apontam para o fechamento transcateter 
do AAE como alternativa para a anticoagulação oral em pacientes selecionados.
© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Publicado por Elsevier Editora Ltda. 
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the lobe, identified by radiopaque markers, which help to secure the 
lobe to the LAA body in the landing zone (Fig. 1).
All procedures were performed under general anesthesia and tra-
cheal intubation, after a minimum fasting period of 8 hours, under 
fluoroscopic and transesophageal echocardiography guidance in the 
interventional cardiology laboratory.
Unfractionated heparin was administered at doses of 5,000 to 
10,000 IU after obtaining transseptal access. Supplemental doses of 
2,500 to 5,000 IU were administered every 30 minutes when the pro-
cedures lasted longer than 1 hour. Antimicrobial prophylaxis with 2 g 
of intravenous cefazolin was routinely administered. The patients 
were submitted to right and left heart catheterization through femo-
ral vein puncture. Left atrial access was obtained by transseptal punc-
ture with the standard technique using a Brockenbrough needle.
With the aid of a calibrated 5 F pigtail catheter, the LAA was 
catheterized and injections were performed in the right anterior 
oblique (RAO) view, with cranial and caudal angulation, to deter-
mine the anatomic type and to obtain measures of the ostium and 
the landing zone of the occluder device’s lobe. The measures 
and anatomy were compared with those obtained with the TEE, 
with the largest measurements utilized to select the prosthesis to 
be implanted (Fig. 2).
The pigtail catheter was removed and replaced by a long guide 
wire (260 cm) with a curved tip (J), rigid or super rigid, inside the 
LAA. Over it, a long, double-curve AGA sheath was introduced, 
with a diameter compatible with the chosen occluder. The sheath 
was positioned as coaxially as possible to the LAA axis and the po-
sition was assessed using manual contrast injections, through the 
hemostatic valve. The chosen device was introduced through the 
sheath, previously loaded in the delivery system, whose lobe dia-
meter was 2 to 4 mm larger than the largest measure obtained 
from the implantation landing zone. The device lobe was ideally 
Figure 1. Occluder details. Note the disc at the bottom of the picture and, above it, the 
lobe, in which six pairs of locking hooks are displayed.
 F. Chamié et al. / Rev Bras Cardiol Invasiva. 2015;23(3):177-182 179
implanted maintaining two-thirds of the lobe in a distal position to 
the left circumflex coronary artery location, visualized by TEE. 
Subsequently, while maintaining slight traction on the delivery ca-
ble, the sheath was retracted, externalizing the disk in order to oc-
clude the LAA ostium. The tension on the cable was maintained for 
a few minutes (tug test) to ensure that the device was well adhered 
to the LAA body, minimizing the risk of embolization or displace-
ment. The evaluated signs of good positioning were the degree of 
compression of the occluder lobe, separation between the disc and 
the lobe, the concave shape of the disc and its position at the os-
tium entrance, and lobe positioning with at least two-thirds within 
the left circumflex coronary artery (Fig. 3). 
New injections were performed through the delivery system, to 
confirm the correct positioning of the device with complete occlu-
sion of the LAA ostium (Fig. 4). After it was considered to be satisfac-
tory, the prosthesis was released from the delivery cable by 
unscrewing it from the delivery system. Immediately after the im-
plantation, the absence of periprosthetic residual flow and pericar-
dial effusion was verified through the TEE.
Patients were awakened in the interventional laboratory and 
taken to the intensive care unit for postoperative care. Another dose 
of 1 g of cefazolin was administered 6 hours after the procedure. 
Patients were discharged on the day after the implantation, after 
being submitted to a control transthoracic echocardiogram (TTE). 
At the follow-up, all patients were instructed to use dual antipla-
telet therapy with 200 mg of acetylsalicylic acid associated with 75 
mg of clopidogrel bisulfate. Medical evaluations followed by echo-
cardiographic assessment were performed after 1 and 3 months, 
when clopidogrel was discontinued. After 6 months, control TEE was 
performed and patients maintained the continuous use of acetylsa-
licylic acid.
Figure 2. Correspondence between angiographic and echocardiographic images. In A, 
the left atrial appendage seen in the cranial-right anterior oblique view shows simi-
larity with the echocardiographic image obtained with the transducer at 55° in B. In 
C, appendage angiography in the right anterior oblique view with caudal angulation 
shows a better depiction of the more terminal trabecular portion of the left atrial 
appendage, which is also seen in D in the echocardiographic image at 132°. 
Figure 3. Three-dimensional transesophageal echocardiography image showing some 
of the signs of adequate device positioning, such as lobe compression and the separa-
tion between the lobe and the disc, which shows a concave configuration, occluding 
the ostium of the left atrial appendage.
Figure 4. Angiography performed through the sheath system showing the disk in-
side the left atrial appendage and complete obliteration of the ostium by the pros-
thesis disc still attached to the delivery system, which would allow its repositioning 
if necessary.
Results 
From March 2014 to August 2015, 14 percutaneous occlusions of 
the LAA were performed in 13 patients. Eight patients were fema-
les. Age ranged from 46 to 83 years (66.7 ± 11.8 years).
Significant bleeding during OAC use was found in nine (69.2%) 
patients. Gastrointestinal bleeding was identif ied in six pa-
tients, and a retinal, genitourinary and intracranial bleeding in 
the remainder.
Seven (53.8%) patients had suffered a previous stroke. Most pa-
tients (84.6%) had permanent AF; in the others, the arrhythmia was 
paroxysmal. Clinical data and the main comorbidities found are des-
cribed in Table 1.
Regarding the shape, bilobulated appendages were present in 
76.9% of cases, whereas the others were single-lobulated. Ostial dia-
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ter the index procedure. Initially, an attempt was made to occlude 
the LAA with a 30-mm ACP, which showed to be oversized and was 
finally replaced by a 28-mm ACP, which adequately occluded the 
appendage (Fig. 6). In the remaining patients, the LAA was occluded 
with a single device. Fifteen ACP and two PFO prostheses were used 
for LAA occlusion (Table 2). 
There was a single periprocedural complication (MPG, case 6). 
The patient had a narrow and shallow appendage, which was perfo-
rated by the hydrophilic guide at the beginning of the procedure. 
She had pericardial effusion, which was promptly drained at the in-
terventional cardiology laboratory. After hemodynamic stabiliza-
tion of the patient, the procedure continued and the LAA was 
occluded with a 16-mm ACP (Fig. 7). The effusion was contained af-
ter appendage occlusion and the patient was transferred to the in-
meter ranged from 13 to 30 mm (23.9 ± 5.4 mm) and the landing 
zone from 11 to 28 mm (20.8 ± 5.1 mm).
The procedure was successful in all cases. Sixteen devices were 
used for occlusion in the 13 patients, at a ratio of 1.2 device per pa-
tient. The other AMPLATZER® PFO Occluder (PFO) prosthesis of 25 
mm was used to occlude the foramen ovale of a patient (SMGQ, case 
4) who did not require transseptal puncture and had her LAA occlu-
ded with ACP through the foramen ovale (Fig. 5). 
Only one patient required more than one prosthesis to occlude 
the LAA (ABB, case 5). He had his occlusion procedure performed as 
a live case during Rio.Interv 2014. At the time, a proximal accessory 
lobe was occluded in the anterosuperior position with a 16-mm ACP, 
and a 25-mm PFO prosthesis was used for the remainder of the 
appendage body, with immediate success. After 2 days, the PFO 
prosthesis migrated to the transverse aorta, from which it was per-
cutaneously removed with a loop snare catheter. As the main body 
of the appendage was uncovered after embolization of the PFO pros-
thesis, a second procedure was offered and carried out 5 months af-
Table 1
Clinical data of patients submitted to left atrial appendage occlusion.
n ID Age 
(years)
Indication Comorbidities CHA2DS2-VASc HAS-BLED Atrial 
fibrillation 
1 AFS 71 Gastrointestinal bleeding + stroke SAH + DM 2 7 5 Paroxysmal
2 JSFF 78 Gastrointestinal bleeding - 3 3 Permanent
3 GC 46 Stroke SAH + DCM 4 3 Paroxysmal
4 SMGQ 66 Retinal bleeding SAH + DAC + PFO 7 4 Permanent
5 ABB 80 Gastrointestinal bleeding + stroke SAH + DM2 7 5 Permanent
6 MPG 53 Labile INR SAH + CAD 3 2 Permanent
7 RSRS 76 Gastrointestinal bleeding SAH + DM2 6 4 Permanent
8 GAS 65 Stroke SAH + DCM 6 4 Permanent
9 HBS 58 Genitourinary bleeding DCM 2 3 Permanent
10 MJML 71 Stroke SAH + CAD 6 4 Permanent
11 AIF 52 IC bleeding + stroke SAH + DCM + hypothyroidism 4 4 Permanent
12 MJB 83 Gastrointestinal bleeding + stroke SAH + DM2 + DCM 8 5 Permanent
13 GSA 76 Gastrointestinal bleeding SAH + DM2 + CAD + DCM 7 4 Permanent
ID: patient identification; SAH: systemic arterial hypertension; DM2: type 2 diabetes mellitus; DCM: dilated cardiomyopathy; CAD: coronary artery disease; PFO: patent foramen ovale; INR: international 
normalized ratio. 
Figure 6. Images from case 5. In A, the accessory lobe occluded with the AMPLATZER® 
16-mm Cardiac Plug and the appendage body occluded with AMPLATZER® 25-mm PFO 
Occluder can be observed. In B, the AMPLATZER® PFO Occluder is embolized into the 
aortic arch, being captured by the loop catheter. In C, at the end of the final procedure, 
the accessory lobe is completely occluded by AMPLATZER® 16-mm Cardiac Plug and the 
body of the left atrial appendage by the second AMPLATZER® 28-mm Cardiac Plug de-
vice. In D, echocardiographic control image after the procedure, showing the ostium of 
the left atrial appendage occluded by AMPLATZER® 28-mm Cardiac Plug device. Observe 
the increase in echocardiographic density in the left atrial appendage corresponding to 
AMPLATZER® 16-mm Cardiac Plug device, which is barely visible in this image.
Figure 5. Images from case 4. The AMPLATZER® 24-mm Cardiac Plug device is seen 
occluding the left atrial appendage and the AMPLATZER® 25-mm PFO Occluder device 
is positioned through the patient's foramen ovale. For the implant of the AMPLATZER® 
PFO Occluder device, the procedure utilized the same double curve sheath that was 
used for the implant of the AMPLATZER® Cardiac Plug device.
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tensive care unit in good condition for post-procedure care. At the 
follow-up, she had persistent pericarditis treated with colchicine 
and corticosteroids; she achieved remission after 30 days and has 
remained asymptomatic since then. 
Follow-up was obtained in all cases. The mean time was 12.2 
months (5 to 19 months) and only one patient had not yet reached 
the 6-month follow-up period. All atrial appendages remained clo-
sed, and no patient had periprosthetic leaks nor thromboembolic 
events to date.
There was one late death, which was unrelated to the procedure. 
The patient (GC, case 3) had severe dilated cardiomyopathy and died 
of refractory heart failure 11 months after the procedure. The pros-
thesis remained correctly positioned and there was no periprosthe-
tic regurgitation.
Discussion
The first, fundamental step in the occlusion procedure is obtai-
ning access to the left atrium. Typically, this is accomplished throu-
gh transseptal puncture with a Brockenbrough needle.14 To access 
and manipulate the long sheath coaxially inside the LAA, it is impor-
tant that the transseptal needle cross the atrial septum in the poste-
roinferior position.13 Visualization by TEE allows the interventionist 
to perform the transseptal puncture precisely in the desired place, 
favoring procedural success.15 Additionally, gaining access to the left 
atrium via atrial septal defects has been described for LAA occlusion. 
The transseptal puncture is avoided and the technique does not pre-
vent the completion of the procedures in most cases.16,17 
The anatomy and the spatial location of the LAA are extremely 
variable, resulting in unique descriptions (cauliflower, cactus, chi-
cken wing, windsock),13 which were not used in this study. The ana-
tomical analysis of the LAA, in this study, was performed through 
transesophageal echocardiography and angiography. A correlation 
was observed between the echocardiographic images obtained with 
the transducer positioned between zero and 60° and the angiograms 
performed in RAO view with cranial angulation, whereas the images 
obtained with the transducer positioned between 90° and 130° were 
better correlated with angiograms obtained in RAO view with cau-
dal angulation, which more precisely delineated the terminal part of 
the trabecular portion of the appendages. In the limited experience 
reported in this article, the RAO view was preferably used with cau-
dal angulation for device implantation, as it has demonstrated the 
highest measured values, and the latter guided the choice of pros-
theses used. 
The LAA, together with its great anatomical variability, is an ex-
tremely delicate and friable structure, which may explain the inci-
dence of pericardial effusion observed in the occlusion procedures, 
ranging from 1.2 to 3.7%.18-21 
Figure 7. Images from case 6. In A, angiography performed through the double curve sheath, showing the small perforation at the tip of the left atrial appendage with contrast 
extravasation into the pericardial cavity. In B, after hemodynamic stabilization of the patient by draining the pericardial effusion with a pigtail catheter, the left atrial appendage 
totally occluded by the AMPLATZER® 16-mm Cardiac Plug device can be observed.
Table 2
Characteristics of occluded appendages and devices used.
n ID Shape Ostium (mm) Landing zone (mm) Devices used
1 AFS Bilobulated 24 22 ACP 26
2 JSFF Single-lobulated 28 26 ACP 30
3 GC Bilobulated 28 28 ACP 30
4 SMGQ Bilobulated 24 17 ACP 24 + PFO 25
5 ABB Bilobulated 26 26 ACP 16 + PFO 25 + ACP 30 + ACP 28
6 MPG Bilobulated 13 11 ACP 16
7 RSRS Bilobulated 19 18 ACP 22 
8 GAS Bilobulated 20 18 ACP 24
9 HBS Single-lobulated 30 22 ACP 26
10 MJML Single-lobulated 16 15 ACP 18
11 AIF Bilobulated 30 24 ACP 28
12 MJB Bilobulated 28 26 ACP 30
13 GSA Bilobulated 25 18 ACP 20
ID: patient identification; ACP: AMPLATZER® Cardiac Plug; PFO: patent foramen ovale.
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Extreme care should be exercised when manipulating it and 
some basic rules need to be followed, such as using only round-
-tip guide wires (J) and striving to maintain the long delivery she-
ath as coaxial as possible to the long axis of the appendage, away 
from its walls. Care must be taken at all times during the proce-
dure with the LAA borders, avoiding at all costs reaching its ex-
tremity with the dilator or long sheath. The learning curve of this 
procedure is significant, and it has been shown that the number 
of procedural complications decreases as the team becomes fami-
liar with the occlusion technique.22,23 
The ACP consists of a lobe and a disk connected by a f lexible 
pin that articulates and allows angulation between them. The 
lobe, which is implanted in the LAA body, has 12 small hooks for 
device stabilization. It is of utmost importance that, to prevent 
embolization of the prosthesis, the lobe undergoes some degree 
of compression, to promote contact between the hooks and the 
LAA walls. For this purpose, it is important to use the largest 
measurements obtained, choosing devices that are 4 to 6 mm 
larger than the landing zone. However, the use of prosthetic de-
vices much larger than the implantation region causes device 
migration, as seen in case 5. An excessively oversized device de-
forms the lobe, modifying the positioning of the hooks, retracting 
them and causing loss of their contact with the LAA wall. The 
same occurs if the selected device is too small, smaller than 
the landing zone, a situation in which also there is no contact of the 
hooks with the LAA wall.
The implantation of the prosthesis should promote appendage 
body occlusion, isolating its entire trabecular portion, whose uneven 
surface creates conditions for the formation of thrombi found in AF. 
The presence of the disc, positioned aiming to obliterate the LAA os-
tium, acts as a second occluder element, increasing procedural safety. 
It is important for the disk to maintain a concave shape and to adapt 
perfectly to the ostium, preventing spaces that can be a source of 
thrombi or even the origin of periprosthetic regurgitation.
It is presumed that periprosthetic residual flow may be the cause 
of new cerebral ischemic strokes and, therefore, should be preven-
ted, although there is some controversy in the literature.24,25 Cur-
rently, residual f lows with diameter ≥ 5 mm are considered as 
significant,26 which, when present, should be occluded with a se-
cond device. The use of more than one device for LAA occlusion has 
been successfully performed and appears to be associated with fa-
vorable results in patient follow-up.27
Conclusions 
The occlusion of the left atrial appendage in this small number of 
cases showed to be safe and effective, in spite of the complexity and 
comorbidities of the patients included in this study.
The initial results are encouraging and, despite the short-term 
follow-up of these patients, they confirm that percutaneous occlu-
sion of the left atrial appendage can become a valid alternative to 
oral anticoagulation in patients who cannot use it.
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